PT2938598T - Derivados de ftalazin-1-(2h)-ona substituídos como inibidores seletivos da poli (adp-ribose) polimerase-1 - Google Patents

Derivados de ftalazin-1-(2h)-ona substituídos como inibidores seletivos da poli (adp-ribose) polimerase-1

Info

Publication number
PT2938598T
PT2938598T PT138289962T PT13828996T PT2938598T PT 2938598 T PT2938598 T PT 2938598T PT 138289962 T PT138289962 T PT 138289962T PT 13828996 T PT13828996 T PT 13828996T PT 2938598 T PT2938598 T PT 2938598T
Authority
PT
Portugal
Prior art keywords
adp
ribose
polymerase
poly
derivatives
Prior art date
Application number
PT138289962T
Other languages
English (en)
Inventor
K Srivastava Brijesh
C Desai Ranjit
R Patel Pankaj
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54198806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2938598(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of PT2938598T publication Critical patent/PT2938598T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PT138289962T 2012-12-31 2013-12-23 Derivados de ftalazin-1-(2h)-ona substituídos como inibidores seletivos da poli (adp-ribose) polimerase-1 PT2938598T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3742MU2012 2012-12-31

Publications (1)

Publication Number Publication Date
PT2938598T true PT2938598T (pt) 2017-02-07

Family

ID=54198806

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138289962T PT2938598T (pt) 2012-12-31 2013-12-23 Derivados de ftalazin-1-(2h)-ona substituídos como inibidores seletivos da poli (adp-ribose) polimerase-1

Country Status (30)

Country Link
US (1) US9598418B2 (pt)
EP (1) EP2938598B1 (pt)
JP (1) JP5930452B2 (pt)
KR (1) KR101652654B1 (pt)
CN (1) CN104918917A (pt)
AP (1) AP2015008439A0 (pt)
AR (1) AR094299A1 (pt)
AU (1) AU2013368842B2 (pt)
BR (1) BR112015012425A2 (pt)
CA (1) CA2890309A1 (pt)
CL (1) CL2015001655A1 (pt)
CO (1) CO7400872A2 (pt)
DK (1) DK2938598T3 (pt)
EA (1) EA201591239A1 (pt)
ES (1) ES2614885T3 (pt)
GE (1) GEP201706691B (pt)
HK (1) HK1210466A1 (pt)
HR (1) HRP20170219T1 (pt)
HU (1) HUE030613T2 (pt)
IL (1) IL238714A0 (pt)
MA (1) MA38080A1 (pt)
MX (1) MX2015006780A (pt)
NZ (1) NZ708255A (pt)
PH (1) PH12015501199B1 (pt)
PL (1) PL2938598T3 (pt)
PT (1) PT2938598T (pt)
SG (1) SG11201503670YA (pt)
TW (1) TWI553005B (pt)
WO (1) WO2014102817A1 (pt)
ZA (1) ZA201503218B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
SI3074400T1 (en) 2013-11-26 2018-03-30 F. Hoffmann-La Roche Ag Octahydro-cyclobut (1,2-c, 3,4-cy) dipyrrole derivatives as autoantaxine inhibitors
AU2015238537B2 (en) 2014-03-26 2019-08-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
PE20180552A1 (es) * 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft デュアルatx/ca阻害剤としての新規な二環式化合物
MA42919A (fr) * 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
WO2017071636A1 (zh) * 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
CN107207504B (zh) * 2015-12-16 2020-03-10 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
AU2017280334C1 (en) 2016-06-24 2022-10-20 AtlasMedx, Inc Phthalazine derivatives as inhibitors of PARP1, PARP2 and/or tubulin useful for the treatment of cancer
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
WO2018167001A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual atx/ca inhibitors
MD3483164T2 (ro) 2017-03-20 2020-07-31 Forma Therapeutics Inc Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
CN109251204A (zh) * 2017-07-13 2019-01-22 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN108164468B (zh) * 2018-02-09 2021-02-02 上海卫岑医药科技有限公司 一种parp抑制剂、其药物组合物、制备方法及应用
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
CN115515939A (zh) * 2020-05-08 2022-12-23 谛希诺生物科技有限公司 具有抑制外核苷酸焦磷酸酶-磷酸二酯酶的活性的新型酞嗪衍生物及它们的用途
EP4304720A1 (en) * 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
EP4370125A1 (en) * 2021-07-16 2024-05-22 Oregon Health and Science University Phthalazinone-based parp-1 inhibitors
WO2023174250A1 (en) * 2022-03-15 2023-09-21 Beigene , Ltd. 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
AU9578901A (en) 2000-10-30 2002-05-15 Kudos Pharm Ltd Phthalazinone derivatives
MXPA05009661A (es) 2003-03-12 2006-03-08 Kudos Pharm Ltd Derivados de ftalazinona.
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN100584840C (zh) 2004-01-05 2010-01-27 阿斯利康(瑞典)有限公司 取代杂环化合物及其应用
CA2577191A1 (en) 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
US20060079510A1 (en) 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
KR20080009200A (ko) 2005-04-06 2008-01-25 아스트라제네카 아베 치환된 헤테로사이클 및 이것의 chk1, pdk1 및pak 억제제로서의 용도
ATE499098T1 (de) 2005-11-25 2011-03-15 Pharma Mar Sa Verwendung von parp-1-hemmern
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
MX347085B (es) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
MX2009012705A (es) 2007-05-25 2009-12-08 Astrazeneca Ab Combinacion de inhibidores de cinasa de control y poli(adp-ribosa)polimerasa-1 para el tratamiento de canceres.
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
ES2524787T3 (es) * 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ(adpリボース)ポリメラーゼ−1阻害剤としての、置換4−(4−フルオロ−3−(ピペラジン−1−カルボニル)ベンジル)フタラジン−1(2h)−オン誘導体
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012071684A1 (en) * 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates,preparation processes and medical uses thereof
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
US20140221314A1 (en) 2011-05-31 2014-08-07 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
US9062061B2 (en) 2011-07-13 2015-06-23 Santen Pharmaceutical Co., Ltd. Compound having PARP inhibitory activity
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
CN106083849A (zh) 2011-12-31 2016-11-09 百济神州有限公司 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物
CN104093714B (zh) 2012-02-09 2016-08-24 默克专利股份公司 作为tank和parp抑制剂的四氢-喹唑啉酮衍生物
CN103242273B (zh) 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Also Published As

Publication number Publication date
EP2938598A1 (en) 2015-11-04
CA2890309A1 (en) 2014-07-03
KR20150091137A (ko) 2015-08-07
MA38080A1 (fr) 2018-02-28
PH12015501199A1 (en) 2015-08-17
NZ708255A (en) 2016-08-26
TWI553005B (zh) 2016-10-11
EA201591239A1 (ru) 2015-10-30
ES2614885T3 (es) 2017-06-02
CL2015001655A1 (es) 2015-10-02
SG11201503670YA (en) 2015-07-30
HRP20170219T1 (hr) 2017-04-07
US20150291603A1 (en) 2015-10-15
GEP201706691B (en) 2017-06-26
JP5930452B2 (ja) 2016-06-08
AU2013368842B2 (en) 2015-11-12
EP2938598B1 (en) 2016-12-21
DK2938598T3 (en) 2017-02-13
MX2015006780A (es) 2015-08-06
TW201441219A (zh) 2014-11-01
AP2015008439A0 (en) 2015-05-31
JP2016504347A (ja) 2016-02-12
AR094299A1 (es) 2015-07-22
BR112015012425A2 (pt) 2017-07-11
CO7400872A2 (es) 2015-09-30
CN104918917A (zh) 2015-09-16
HK1210466A1 (en) 2016-04-22
KR101652654B1 (ko) 2016-08-30
PH12015501199B1 (en) 2015-08-17
ZA201503218B (en) 2016-01-27
WO2014102817A1 (en) 2014-07-03
IL238714A0 (en) 2015-07-01
PL2938598T3 (pl) 2017-05-31
AU2013368842A1 (en) 2015-05-21
HUE030613T2 (en) 2017-05-29
US9598418B2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
HRP20170219T1 (hr) Supstituirani derivati ftalazin-1(2h)-ona kao selektivni inhibitori poli(adp-riboza)polimeraze-1
HK1216645A1 (zh) 大環噠嗪酮衍生物
ZA201406078B (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
SI2857404T1 (sl) Imidazo(1,2-b)piridazin derivati kot kinazni inhibitorji
IL238553B (en) Modified indole-5-ol derivatives, preparations containing them and methods for their preparation
HK1206278A1 (en) Fused heterocyclic compounds as selective bmp inhibitors bmp
HK1216147A1 (zh) 取代的苯甲酰基 -氟- -亞氨基- -甲基- -二氫嘧啶- -酮衍生物
PT2935244T (pt) Novos derivados de benzimidazole como inibidores de quinases
ZA201301951B (en) Benzimidazole derivatives as p13 kinase inhibitors
ZA201303614B (en) Quinazolin-4(3h)-one derivatives used as p13 kinase inhibitors
HK1214475A1 (zh) 經取代的 -氟- -亞胺基- -甲基- -側氧基- -二氫嘧啶- -甲酸酯衍生物
HK1207642A1 (en) Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors c-met
HK1166076A1 (en) Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors parp-1 -1(2h)-
SG11201500732TA (en) (aza-)isoquinolinone derivatives
HK1222396A1 (zh) 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物
GB2521802B (en) Reissue of crypographic credentials
HK1200166A1 (en) 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors parp-1 3---1(2h)-